No, I mean that ABBV does not have a "maximize SVR" positioning strategy. GILD still has the "simplest, safest, shortest, highly-effective interferon and ribavirin free" positioning which is all they need to dominate this market. The only way they can lose some of it is due to pricing/contracting competition.
Market Data 
Markets 
AI
